Biocytogen Pharms (Beijing) (2315) fair value: what the stock is really worth
As of Nov 13, 2026: fair value (intrinsic value) of Biocytogen Pharms (Beijing) stock HK$36.26, price HK$41.40, that is 12.4% below the price, quality 58 out of 100. Rating: overvalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Biocytogen Pharms (Beijing)
2315 · HKExpensive (fair value 12% below the price), but solid company and rising price: meets 2 of 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 14, 2026.
How to read this chart
50‑month range HK$5.60 – HK$79.70 · fair‑value band HK$25.38 – HK$47.14 · the HK$41.40 price screens above the HK$36.26 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 14, 2026.
Every Wednesday you see whether Biocytogen Pharms (Beijing) is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a biotechnology company, engages in the research and development of novel antibody-based drugs and pre-clinical research services in the People's Republic of China, the United States, and internationally.
Show moreShow less
It operates through five segments: Gene-Editing; Pharmacological Efficacy; Model Animals; Antibody Development; and Other.
The company provides the customized gene editing services based on animals and cells to meet the needs of basic science research and drug development of the customers; provides the pre-clinical pharmacology service for drug efficacy and toxicity evaluation; engages in breeding and selling animal models for the external and internal use, including set of genetically engineered mice, disease mouse models and aged small animals; engages un utilizing the Group's own antibody discovery platforms to identify antibodies which have the potential to become drug candidates; and engages in research and development of innovative drugs with a focus on oncology and autoimmune disease therapeutics.
The company also offers YH001, a recombinant humanized anti-cytotoxic t-lymphocyte associated protein 4 immunoglobulin G1 (IgG1) monoclonal antibody for the treatment of patients with advanced solid tumors; It also develops YH002, a recombinant humanized IgG1 antibody that targets the human tumor necrosis factor receptor superfamily, member 4 receptor, which is Phase I clinical trial.
The company has collaboration with Syncromune, Inc.; a license agreement with RemeGen Co., Ltd.; license agreement with Chipscreen NewWay Biosciences. Biocytogen Pharmaceuticals (Beijing) Co., Ltd. was founded in 2008 and is headquartered in Beijing, China.
Stock analysis
Biocytogen Pharms (Beijing) (2315) currently trades at HK$41.40, while our model-based Fair Value estimate is HK$36.26, 12% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of HK$27.20 per share, and 0 of the 24 models we run sit above the HK$41.40 price.
Bear case: the Economic Profit group reads lowest at HK$11.11, and 24 of the 24 models stay below the price. Data coverage for this calculation is medium.
Scenario range: HK$25.38 (bear) to HK$47.14 (bull), the price of HK$41.40 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 58/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Biocytogen Pharms (Beijing) reported revenue of 1.4B CNY in FY2025 versus 355M CNY in FY2021, a compound +40.4%/yr. Reported net income was 173M CNY in FY2025.
Key figures
Market cap HK$18.4B (≈ $2.3B) Mid · P/E ratio 43.7 · P/S ratio 5.49 · Net margin 12.6% · Return on equity 22.1% · Return on assets (EBIT) −7.5% (5-year average) · Operating margin 35.4% · Revenue (TTM) 1.7B CNY.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 76 out of 100 (low confidence).
What moves the price
The share trades about 48% below its 52-week high and 61% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −12%, 2315 screens richer than that median.
Fair Value models
All 24 models by family
The fair value above starts from this blend and is adjusted for dilution from new shares.
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
Growth Forecast
Compare Biocytogen Pharms (Beijing) with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 850 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- EBIT margin by industry
- P/S ratio by industry
- Stock screener with 62 metrics
- Undervalued stocks: Hong Kong Stocks
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $955.47 | $1,275 | +33% | vs 2315 |
| Genmab A/S GMAB | kr 3,448 | kr 3,917 | +14% | vs 2315 |
| Vertex Pharmaceuticals Incorporated VRTX | $538.60 | $592.46 | +10% | vs 2315 |
| Samsung Biologics Co 207940 | 1,411,000 KRW | 1,552,100 KRW | +10% | vs 2315 |
| argenx SE ARGX | $960.04 | $908.40 | −5% | vs 2315 |
| CSL Limited CSL | A$202.92 | A$185.51 | −9% | vs 2315 |
| Moderna, Inc MRNA | $223.37 | $139.99 | −37% | vs 2315 |
| Roivant Sciences Ltd ROIV | $39.53 | $19.47 | −51% | vs 2315 |
| Celltrion, Inc 068270 | 214,000 KRW | 74,945 KRW | −65% | vs 2315 |
| Royalty Pharma plc RPRX | $69.31 | $19.01 | −73% | vs 2315 |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Biocytogen Pharms (Beijing) (2315) overvalued or undervalued?
What is the fair value of 2315?
What is the quality score of 2315?
What is the price target for Biocytogen Pharms (Beijing) (2315)?
What is the Biocytogen Pharms (Beijing) stock forecast for 2026?
What is the revenue of Biocytogen Pharms (Beijing) (2315)?
What growth is priced into Biocytogen Pharms (Beijing) (2315)?
What discount rate (WACC) does the fair value of 2315 use?
What is a reverse DCF?
How much growth has Biocytogen Pharms (Beijing) (2315) delivered so far?
How fast is the sector of Biocytogen Pharms (Beijing) (2315) growing?
What is the free cash flow yield of Biocytogen Pharms (Beijing) (2315)?
What is the intrinsic value of Biocytogen Pharms (Beijing) (2315)?
Is Biocytogen Pharms (Beijing) stock overvalued or undervalued in 2026?
Is fair value the same as the market price of 2315?
How much is Biocytogen Pharms (Beijing) worth?
What do the bullish and bearish scenarios say about 2315?
What is the P/E ratio of 2315?
How solid is the balance sheet of Biocytogen Pharms (Beijing) (2315)?
How far is 2315 from its 52-week high?
Which stocks are comparable to Biocytogen Pharms (Beijing)?
Is Biocytogen Pharms (Beijing) stock attractive at the current price?
How is the fair value of 2315 calculated?
Is it still worth investing in stocks now?
What is the share price of Biocytogen Pharms (Beijing) (2315)?
What should I pay attention to with Biocytogen Pharms (Beijing) right now?
Key figures of Biocytogen Pharms (Beijing)
How large is the market capitalisation of Biocytogen Pharms (Beijing) (2315)?
What is the P/S ratio of Biocytogen Pharms (Beijing) (2315)?
What is the net margin of Biocytogen Pharms (Beijing) (2315)?
What is the return on equity of Biocytogen Pharms (Beijing) (2315)?
What is the EBIT return on assets of Biocytogen Pharms (Beijing) (2315)?
What is the operating margin of Biocytogen Pharms (Beijing) (2315)?
How fast is revenue growing at Biocytogen Pharms (Beijing) (2315)?
How fast are earnings growing at Biocytogen Pharms (Beijing) (2315)?
How much net cash does Biocytogen Pharms (Beijing) (2315) hold?
Watch Biocytogen Pharms (Beijing) in the live analysis
One click puts Biocytogen Pharms (Beijing) on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.